Trial reportThe Kaohsiung journal of medical sciences2025
Dexmedetomidine as a Ropivacaine Adjuvant in a Thoracic Paravertebral Block Combined With an Erector Spinae Plane Block for Improving Early Quality of Recovery After Transapical Transcatheter Aortic Valve Implantation.
Trial report in The Kaohsiung journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dexmedetomidine as a Ropivacaine Adjuvant in a Thoracic Paravertebral Block Combined With an Erector Spinae Plane Block for Improving Early Quality of Recovery After Transapical Transcatheter Aortic Valve Implantation.The Kaohsiung journal of medical sciences · 2025Trial
- Design and Application of Intelligent Local Anesthetic Nanoformulations.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study aimed to investigate the effectiveness of dexmedetomidine (Dex) as an adjuvant for ropivacaine in a thoracic paravertebral block (TPVB) combined with an erector spinae plane block (ESPB) for improving early quality of recovery and postoperative pain after transapical transcatheter aortic valve implantation (TAVI). A total of 89 patients who were scheduled to undergo transapical TAVI under general anesthesia were allocated into Group RS and Group RD by using a computer-generated random-number list. Group RS (n = 45) received 35 mL of 0.5% ropivacaine with 5 mL of a normal saline mixture in TPVB combined with ESPB and Group RD (n = 44) received 35 mL of 0.5% ropivacaine with 1 μg/kg Dex in 5 mL of normal saline. The RD group exhibited significantly higher global QoR-15 scores with lower visual analog scale (VAS) scores at 12 and 24 h postoperatively than the RS group. The RD group needed fewer press times of PCIA than the RS group. The postoperative sufentanil consumption was significantly less in the RD group than that in the RS group. A longer time to first use of flurbiprofen with less remedial doses of flurbiprofen consumption within 48 h postoperatively was required for the RD group than that for the RS group. The two groups did not differ in the incidence of side effects. The findings of the study suggest that adding Dex to ropivacaine in TPVB combined with ESPB is effective in improving early quality of recovery and alleviating postoperative pain for patients undergoing transapical TAVI under general anesthesia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.